Archer Materials Eyes Q3 2026 Qubit Demo as Manufacturing Scales to Wafer Level
Archer Materials continues advancing its quantum technology development across computing, sensing, and medical diagnostics programmes, with the company maintaining its Q3CY26 target for demonstrating a working qubit. The ASX-listed semiconductor technology company has completed initial full-wafer graphene manufacturing runs, marking progress in transitioning from laboratory-scale devices toward wafer-scale production using industry-standard semiconductor processes.
Archer Materials advances toward Q3 2026 qubit demonstration as global quantum investment accelerates
Archer is positioning itself as a quantum technology company developing semiconductor devices for quantum computing, quantum sensing, and medical diagnostics applications. The company remains on track toward demonstrating a working qubit by Q3CY26, representing a potential validation milestone for its 12CQ qubit technology.
The transition from laboratory-scale prototypes to wafer-scale manufacturing addresses a critical commercialisation challenge. Archer has completed initial full-wafer graphene manufacturing runs with fabrication partners, moving beyond individual hand-built devices toward processes compatible with existing semiconductor supply chains.
This progress occurs amid accelerating global investment in quantum technologies. Governments and major technology companies are increasing funding commitments, with the United States Government recently committing significant capital to quantum technology companies and quantum foundry infrastructure — signalling the sector’s transition from research phase toward strategically critical industry status.
The qubit milestone represents a potential inflection point for Archer’s technology validation, whilst wafer-scale manufacturing progress addresses a commercialisation pathway that many quantum developers have yet to establish.
When big ASX news breaks, our subscribers know first
Understanding wafer-scale quantum manufacturing
Current quantum devices are typically hand-built, one-off prototypes constructed in research laboratories. These bespoke devices cannot scale economically to support commercial quantum computing systems, which will ultimately require thousands or millions of qubits operating together.
Semiconductor foundries manufacture conventional chips at massive scale using standardised processes on silicon wafers — large circular discs that serve as the base for producing multiple chips simultaneously. A single wafer can yield hundreds or thousands of identical chips through automated, repeatable manufacturing processes.
Archer’s strategy focuses on developing quantum technologies compatible with these existing semiconductor manufacturing processes rather than requiring entirely new production infrastructure. This approach aims to leverage the decades of investment, technical expertise, and established supply chains that already exist within the semiconductor industry.
Manufacturability is increasingly viewed as a key differentiator amongst quantum technology developers. Scientific breakthroughs that cannot transition from laboratory demonstrations to scalable production have limited commercial value, regardless of their performance in controlled research environments.
Key milestones delivered and 2026 targets
Archer’s development roadmap spans multiple programmes across quantum computing, quantum machine learning, and biosensor technologies. Progress across these programmes provides investors with accountability markers and execution visibility.
| Period | Programme | Milestone / Status |
|---|---|---|
| 2024–2025 | 12CQ qubit programme | Gating behaviour and single-electron transistor devices demonstrated; electrically detected magnetic resonance (EDMR) results achieved; cryogenic TMR sensor performance demonstrated |
| Early 2026 | QML programme | Initial simulations and benchmarking completed with testing commenced on AWS quantum hardware |
| February 2026 | Ecosystem partnerships | Emergence Quantum Phase I commenced; QMUL, EPFL, CSIRO partnerships active across hardware, sensing and software |
| May 2026 | Manufacturing transition | Multiple fabrication and testing cycles completed; wafer-scale, foundry-compatible manufacturing transition underway |
| Q3CY26 target | Qubit milestone | Demonstration of working qubit |
| Year-end 2026 target | QML prototype | Full QML fraud detection prototype |
| 2026 target | Biosensor beta prototype | Device suitable for external use and trials |
The 12CQ qubit programme has demonstrated gating behaviour, single-electron transistor functionality, and electrically detected magnetic resonance (EDMR) results, alongside cryogenic TMR sensor performance. The quantum machine learning programme completed initial simulations in early 2026, with benchmarking activities validating performance on both quantum simulators and commercial quantum hardware.
Partnership activities expanded in February 2026, with the Emergence Quantum Phase I programme commencing alongside active collaborations with Queen Mary University of London (QMUL), École Polytechnique Fédérale de Lausanne (EPFL), and CSIRO spanning hardware development, sensing applications, and software integration.
Manufacturing progress accelerated in May 2026, with multiple fabrication and testing cycles completed as the company progressed toward wafer-scale, foundry-compatible production processes. The milestone structure provides investors with a clear roadmap across Archer’s three core technology programmes.
Quantum machine learning delivers promising fraud detection results
Archer successfully completed the initial simulation and benchmarking phase for its CSIRO-supported quantum machine learning fraud detection project. The development team constructed and tested a quantum neural network using a publicly available financial fraud dataset, yielding promising initial performance results.
QML fraud detection simulations used over 280,000 real bank transaction records, with data preprocessing techniques applied to reduce complexity and ensure compatibility with the limited qubit counts available on present-day quantum hardware.
Validation extended beyond simulations to real quantum hardware. The model was successfully executed on the IQM Garnet commercial 20-qubit quantum computer, accessed through the AWS Braket platform. This demonstration confirmed the quantum neural network’s operability on commercial quantum systems rather than exclusively on theoretical simulators.
The company targets delivery of a full QML fraud detection prototype by year-end 2026. Demonstrating competitive performance on commercial quantum hardware validates the practical applicability of Archer’s quantum machine learning approach beyond laboratory simulations.
Biochip programme progresses toward clinical pathway
Following the previously announced beta prototype milestone in May 2026, Archer is advancing engagement activities with Contract Development and Manufacturing Organisations (CDMOs). These partnerships represent a concrete step toward clinical trials and regulatory approval pathways.
The biosensor beta prototype is designed as a user-ready, manufacturable handheld system, a significant upgrade over the lab-level alpha configuration, with early feasibility testing for lithium monitoring in blood now underway and potentially expanding the platform’s commercial applications into bipolar disorder management alongside the primary potassium sensing use case.
CDMOs provide specialised capabilities essential for translating laboratory prototypes into clinically deployable products. These capabilities include design for manufacture, process validation, quality management systems, and production capabilities under regulated conditions that meet medical device manufacturing standards.
Establishing these partnerships early reduces development risk by identifying manufacturing constraints before clinical trials commence. CDMO engagement supports future manufacturing readiness whilst positioning the Biochip technology for clinical evaluation and regulatory submissions required for commercial deployment.
The company is also pursuing commercial engagement opportunities associated with the programme, moving the Biochip from laboratory prototype toward potential market introduction.
Strategic acquisition review targets complementary technologies
Archer is actively reviewing potential acquisitions of complementary products, intellectual property, and technology platforms consistent with its quantum technology strategy. The company has commenced discussions with several technology companies and institutions regarding potential transactions.
The acquisition criteria being assessed include:
- Accelerating Archer’s quantum technology roadmap
- Broadening the company’s product and intellectual property portfolio
- Strengthening positioning in quantum computing, sensing, and semiconductor-enabled diagnostics
- Providing nearer-term commercial pathways alongside longer-term development programmes
- Expanding access to customers, technical partners, manufacturing capability, or specialised technical teams
The company emphasised that discussions remain incomplete and non-binding, with no certainty that any transaction will proceed. Archer stated it will update the market in accordance with continuous disclosure obligations if and when binding agreements or material developments occur.
Strategic M&A activity signals management is actively seeking to accelerate commercialisation timelines and expand addressable market opportunities beyond the company’s existing internal development programmes.
CEO outlines quantum industry momentum
Dr. Simon Ruffell, CEO
“Quantum technology is moving rapidly from a research theme into a strategic global industry. Governments, semiconductor companies and major technology groups are now investing heavily in quantum because of its potential importance to AI, computing, sensing, national security, healthcare and advanced manufacturing.”
Dr. Ruffell noted that Archer has been developing its quantum technology capability for many years, with the strategy now coming together across qubit development, quantum sensing, quantum machine learning, and semiconductor-enabled medical diagnostics.
He added that the company is actively assessing opportunities to acquire complementary products, intellectual property, and technology platforms capable of accelerating the overall strategy. The CEO stated that Archer is in advanced discussions with several companies and will only proceed where opportunities are strategically aligned and capable of creating long-term shareholder value.
The next major ASX story will hit our subscribers first
Investment outlook and near-term catalysts
Key catalysts investors should monitor over the coming quarters include:
- Q3CY26 qubit demonstration outcome — represents the primary near-term technical validation milestone for the 12CQ quantum computing programme
- QML fraud detection prototype completion (year-end 2026) — will demonstrate commercial application of quantum machine learning technology on real-world datasets
- Biosensor beta prototype delivery and external trial commencement — marks transition from internal development to clinical pathway activities with external validation
- Potential acquisition or partnership announcements — could accelerate commercialisation timelines and expand technology portfolio beyond existing internal development programmes
Archer’s strategic positioning centres on developing technologies that are scientifically differentiated whilst remaining manufacturable and scalable through integration with existing semiconductor supply chains. This approach distinguishes the company from quantum developers pursuing technologies that may require entirely new manufacturing infrastructure, though successful execution across multiple simultaneous programmes remains critical to commercial validation.
Want the Next Quantum Tech Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX news delivered within minutes of release, complete with in-depth analysis. Big News Blast alerts cover Tech, Healthcare, Finance, and other non-resource sectors. Click the “Free Alerts” button at StockWire X to start receiving market-moving announcements the moment they break.